Both e-cigarettes and ordinary tobacco are associated with oral cancer

Share This Post

At the 96th Congress of the International Association for Dental Research (IADR), Benjamin Chaffee of the University of California, San Francisco published a report on nicotine and carcinogens in tobacco.

Tobacco use is still the main cause of oral cancer, but with the increase in the use of non-cigarette tobacco products and the dual use of multiple product types, the tobacco growing industry has been developing. The study reported on the assessment of exposure to known carcinogens of different types of tobacco products used alone or in combination.

The data comes from the tobacco and healthy population assessment, which includes a sample of American adults who provide urine samples for analysis of tobacco-specific nitrosamines (TSNAs) N’-nitroso-nornicotinine (NNN), which is A known carcinogen of the mouth and esophagus.

Classified according to the way of tobacco use, including cigarettes, cigars, hookahs, pipe tobacco, blunt (cigars containing hemp) and smokeless, such as including wet snuff, chewing tobacco and snuff are electronic cigarettes and nicotine replacement products. For each product, the most recent use refers to the previous 3 days, and the non-use refers to no smoking within 30 days.

All tobacco use categories show increased nicotine and TSNA concentrations relative to non-users. TSNA has the highest exposure to smokeless tobacco users, whether used alone or with other types of products. Although nicotine exposure is comparable, the levels of NNN and NNAL using only e-cigarettes are lower than other tobacco categories. However, the simultaneous use of combustible tobacco by most e-cigarette users resulted in TSNA exposure similar to that of exclusive smokers.

Analysis shows that the majority of non-cigarette tobacco users are exposed to carcinogens that are at or above the exposure levels of exclusive cigarette smokers, and may still face significant risks.

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

PiggyBac Transposon System
AI & Technology

PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy

The PiggyBac Transposon System is revolutionizing genetic engineering in cancer research, especially in CAR T-cell therapy. With its high integration efficiency and large cargo capacity, it provides a powerful, non-viral alternative to traditional gene delivery methods. Learn how PiggyBac is advancing personalized cancer treatment and shaping the future of oncology.

Breakthrough 2025 Treatments for Advanced Breast Cancer
Biotech Innovations

Breakthrough Treatments for Advanced Breast Cancer in 2025

In 2025, advanced breast cancer treatment has entered a new era. Precision medicine and targeted therapies are enabling doctors to tailor care based on genetic profiles. Immunotherapy and antibody-drug conjugates are delivering more effective tumor targeting, while experimental cellular treatments like CAR T-cell therapy show immense promise. These cutting-edge options are transforming outcomes and quality of life for patients facing metastatic breast cancer. Explore the latest innovations driving hope and progress.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

We Are Online! Chat With Us!
Scan the code